|
Burzynski Research Institute Inc (BZYR) |
|
Burzynski Research Institute Inc
BZYR's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Burzynski Research Institute Inc's sales fell
in II. Quarter 2024 from the same quarter a year ago.
In Vitro & In Vivo Diagnostic Substances industry recorded
growth of revenues by 5.93 %
Burzynski Research Institute Inc net loss increased from $0 millions, to $0 millions in II. Quarter 2024,
• More on BZYR's Growth
|
|
Burzynski Research Institute Inc realized a net loss in trailing twelve months.
Burzynski Research Institute Inc realized cash reduction of $ -0 per share in trailing twelve-month period. In Vitro & In Vivo Diagnostic Substances industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 7.68.
• More on BZYR's Valuation
|
|
|
|
|
Burzynski Research Institute Inc realized net loss in trailing twelve months.
Burzynski Research Institute Inc realized cash outflow of $ -0per share in trailing twelve-month period. In Vitro & In Vivo Diagnostic Substances industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 7.68.
• More on BZYR's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com